BioTelemetry (BEAT) Tops Q4 EPS by 5c
BioTelemetry (NASDAQ: BEAT) reported Q4 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $54 million versus the consensus estimate of $53.75 million.
For earnings history and earnings-related data on BioTelemetry (BEAT) click here.